High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 2012;62(5):283-98
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Fletcher GH. Clinical dose-response curves of human malignant epithelial tumours. Br J Radiol 1973;46(541):1-12
   PubMed Web of Science ®Google Scholar
• Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20(5):1167-74
   PubMed Web of Science ®Google Scholar
• Suh YG, Lee IJ, Koom WS, et al. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Jpn J Clin Oncol 2014;44(6):534-40
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281(17):1623-7
   PubMed Web of Science ®Google Scholar
• al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Am Clin Oncol 1997;15(1):277-84
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326(24):1593-8
   PubMed Web of Science ®Google Scholar
• Streeter Jr O, Martz K, Gaspar L, et al. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG# 85-01? Int J Radiat Oncol Biol Phys 1999;44(5):1047-52
   PubMed Web of Science ®Google Scholar
• Cho SH, Shim HJ, Lee SR, et al. Concurrent chemoradiotherapy with S-1 and cisplatin in advanced esophageal cancer. Dis Esophagus 2008;21(8):697-703
   PubMed Web of Science ®Google Scholar
• Crosby TD, Brewster AE, Borley A, et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004;90(1):70-5
   PubMed Web of Science ®Google Scholar
• Conroy T, Yataghene Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010;103(9):1349-55
   PubMed Web of Science ®Google Scholar
• Kato K, Nakajima TE, Ito Y, et al. Phase II Study of Concurrent Chemoradiotherapy at the Dose of 50.4 Gy with Elective Nodal Irradiation for Stage II–III Esophageal Carcinoma. Jpn J Clin Oncol 2013;43(6):608-15
   PubMed Web of Science ®Google Scholar
• Michel P, Adenis A, Di Fiore F, et al. Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer 2006;95(6):705-9
   PubMed Web of Science ®Google Scholar
• Waters JS, Tait D, Cunningham D, et al. A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus. Ann Oncol 2002;13(11):1763-70
   PubMed Web of Science ®Google Scholar
• Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer. Cancer Chemother Pharmacol 2012;70(5):683-90
   PubMed Web of Science ®Google Scholar
• Zhao T, Chen H, Zhang T. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Med Oncol 2012;29(5):3017-23
   PubMed Web of Science ®Google Scholar
• Hejna M, Kornek GV, Schratter-Sehn AU, et al. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma. Cancer 1996;78(8):1646-50
   PubMed Web of Science ®Google Scholar
• Poplin EA, Jacobson J, Herskovic A, et al. Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. Cancer 1996;78(9):1851-6
   PubMed Web of Science ®Google Scholar
• Servagi-Vernat S, Bosset M, Crehange G, et al. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study. Drugs Aging 2009;26(3):255-62
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008;26(28):4551-6
   PubMed Web of Science ®Google Scholar
• Bidoli P, Bajetta E, Stani SC, et al. Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus. Cancer 2002;94(2):352-61
   PubMed Web of Science ®Google Scholar
• Palie O, Michel P, Ménard JF, et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013;40(9):1345-55
   PubMed Web of Science ®Google Scholar
• Conroy T, Galais MP, Raoul JL, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15(3):305-14
   PubMed Web of Science ®Google Scholar
• Ordu AD, Nieder C, Geinitz H, et al. Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus : Long-term outcome. Strahlenther Onkol 2014;191(2):153-60
   PubMed Web of Science ®Google Scholar
• Honing J, Smit JK, Muijs CT, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol 2014;25(3):638-43
   PubMed Web of Science ®Google Scholar
• Button MR, Morgan CA, Croydon ES, et al. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;73(3):818-23
   PubMed Web of Science ®Google Scholar
• Gupta A, Roy S, Majumdar A, et al. A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer. Indian J Med Paediatr Oncol 2014;35(1):54-9
   PubMedGoogle Scholar
• Amini A, Ajani J, Komaki R, et al. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol 2014;21(1):306-14
   PubMed Web of Science ®Google Scholar
• Higuchi K, Komori S, Tanabe S, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 2014;89(4):872-9
   PubMed Web of Science ®Google Scholar
• Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 2013;14(7):627-37
   PubMed Web of Science ®Google Scholar
• Minsky BD, Neuberg D, Kelsen DP, et al. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol 1996;14(1):149-55
   PubMed Web of Science ®Google Scholar
• Minsky BD, Neuberg D, Kelsen DP, et al. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999;43(3):517-23
   PubMed Web of Science ®Google Scholar
• Lee SJ, Ahn BM, Kim JG, et al. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci 2009;24(1):120-5
   PubMed Web of Science ®Google Scholar
• Denham JW, Burmeister BH, Lamb DS, et al. Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol 1996;40(1):31-43
   PubMed Web of Science ®Google Scholar
• Kato K, Muro K, Minashi K, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 2011;81(3):684-90
   PubMed Web of Science ®Google Scholar
• Onozawa M, Nihei K, Ishikura S, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009;92(2):266-9
   PubMed Web of Science ®Google Scholar
• Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003;21(14):2697-702
   PubMed Web of Science ®Google Scholar
• Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T< sub> 2–3</sub> N< sub> any</sub> M< sub> 0</sub> squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003;57(2):425-33
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999;17(9):2915-21
   PubMed Web of Science ®Google Scholar
• Kumar S, Dimri K, Khurana R, et al. A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus. Radiother Oncol 2007;83(2):139-47
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Mitsumori M, Hiraoka M, et al. A randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer: Short-term infusion versus protracted infusion chemotherapy (KROSG0101/JROSG021). Radiother Oncol 2009;92(2):260-5
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Yoshida S, Boku N, et al. Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 1995;25(6):261-6
   PubMed Web of Science ®Google Scholar
• Roca E, Pennella E, Sardi M, et al. Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer. Eur J Cancer 1996;32A(3):429-32
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Denham JW, O’Brien M, et al. Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. Int J Radiat Oncol Biol Phys 1995;32(4):997-1006
   PubMed Web of Science ®Google Scholar
• Ruhstaller T, Templeton A, Ribi K, et al. Intense therapy in patients with locally advanced esophageal cancer beyond hope for surgical cure: a prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie 2010;33(5):222-8
   PubMed Web of Science ®Google Scholar
• Ishida K, Iizuka T, Ando N, Ide H. Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: nine Japanese institutions trial. Jpn J Clin Oncol 1996;26(5):310-15
   PubMed Web of Science ®Google Scholar
• Iwase H, Shimada M, Tsuzuki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial. Oncology 2013;84(6):342-9
   PubMed Web of Science ®Google Scholar
• Shen ZT, Wu XH, Li B, et al. Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma. World J Gastroenterol 2013;19(48):9447-52
   PubMed Web of Science ®Google Scholar
• Roeder F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiation Oncology 2014;9(1):191
   PubMed Web of Science ®Google Scholar
• Zhang P, Xi M, Zhao L, et al. Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma? PLoS One 2014;9(8):e105270
   Google Scholar
• Zhang X, Li M, Meng X, et al. Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol 2014;9:64
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Sohda M, Tanaka N, et al. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol 2014;75(3):449-55
   PubMed Web of Science ®Google Scholar
• Liu M, Zhao K, Chen Y, Jiang GL. Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis. Radiat Oncol 2014;9(1):232
   PubMed Web of Science ®Google Scholar
• Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009;75(1):122-8
   PubMed Web of Science ®Google Scholar
• Welsh J, Settle SH, Amini A, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012;118(10):2632-40
   PubMed Web of Science ®Google Scholar
• Settle S, Bucci M, Palmer M, et al. PET/CT fusion with treatment planning CT (TP CT) shows predominant pattern of locoregional failure in esophageal patients treated with chemoradiation (CRT) is in GTV. Int J Radiat Oncol Biol Phys 2008;72(1):S72-3
   Google Scholar
• Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014;32(30):3400-5
   PubMed Web of Science ®Google Scholar
• Hofstetter WL. Salvage esophagectomy. J Thorac Dis 2014;6(Suppl 3):S341-9
   Google Scholar
• Watanabe M, Mine S, Nishida K, et al. Salvage esophagectomy after definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: who really benefits from this high-risk surgery? Ann Surg Oncol 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Chen Y, Lu Y, Wang Y, et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus 2014;27(2):134-40
   PubMed Web of Science ®Google Scholar
• Yoo C, Park JH, Yoon DH, et al. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer. The Ann Thorac Surg 2012;94(6):1862-8
   PubMed Web of Science ®Google Scholar
• Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2009;137(1):49-54
   PubMed Web of Science ®Google Scholar
• Roeder F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol 2014;9:191
   PubMed Web of Science ®Google Scholar
• Rackley T, Leong T, Foo M, Crosby T. Definitive chemoradiotherapy for oesophageal cancer – a promising start on an exciting journey. Clin Oncol 2014;26(9):533-40
   Web of Science ®Google Scholar
• Kole TP, Aghayere O, Kwah J, et al. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2012;83(5):1580-6
   PubMed Web of Science ®Google Scholar
• Nkhali L, Thureau S, Edet-Sanson A, et al. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses. Acta oncologica 2014;1-7
   Google Scholar
• NCT 01937208: Cámara de Comercio de Bogotá. Available from: www.google.co.in/search?q=NCT+01937208&ie=utf-8&oe=utf-8&gws_rd=cr&ei=DZynVa36NcOHuASAwriICQ
   Google Scholar